181 related articles for article (PubMed ID: 2523157)
1. Reactivity of patient antisera to OKT3 with a panel of CD3 monoclonal antibodies.
Nashan B; Schwinzer R; Wonigeit K; Pichlmayr R
Transplant Proc; 1989 Feb; 21(1 Pt 1):985-6. PubMed ID: 2523157
[No Abstract] [Full Text] [Related]
2. The human antimouse reaction to OKT3: cross-reactive pattern analysis using a large group of anti-CD3 and isotypic monoclonal antibodies.
Shield CF; Hughes JD; Marlett P; Norman DJ
Transplant Proc; 1989 Feb; 21(1 Pt 1):981-4. PubMed ID: 2523156
[No Abstract] [Full Text] [Related]
3. An overview of the use of the monoclonal antibody OKT3 in renal transplantation.
Norman DJ
Transplant Proc; 1988 Dec; 20(6):1248-52. PubMed ID: 2974204
[TBL] [Abstract][Full Text] [Related]
4. Immunologic monitoring with Orthoclone OKT3 therapy.
Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
[TBL] [Abstract][Full Text] [Related]
5. RIV-9: a mouse IgG3 anti-human CD3 monoclonal antibody with strong antigen modulating and T cell eliminating properties.
Vaessen LM; Kreeftenberg JG; Heyse P; Leerling MF; Baumgartner D; Hendriks GF; Jutte NH; Weimer W
Transplant Proc; 1989 Feb; 21(1 Pt 1):1026-7. PubMed ID: 2523112
[No Abstract] [Full Text] [Related]
6. Are OKT3 binding sites on T cells modulated or merely converted (blindfolded) by OKT3 during therapy?
Carreno M; Miller J; Esquenazi V; Milgrom M; Roth D; Fuller L
Transplant Proc; 1989 Feb; 21(1 Pt 1):987-8. PubMed ID: 2565060
[No Abstract] [Full Text] [Related]
7. Usefulness of CD3 or CD6 anti-T monoclonal antibodies in the treatment of acute corneal graft rejection.
Ippoliti G; Fronterrè A
Transplant Proc; 1989 Feb; 21(1 Pt 3):3133-4. PubMed ID: 2523173
[No Abstract] [Full Text] [Related]
8. Kinetics of interleukin 6 during OKT3 treatment in renal allograft recipients.
Bloemena E; ten Berge IJ; Surachno J; Wilmink JM
Transplantation; 1990 Aug; 50(2):330-1. PubMed ID: 2143327
[No Abstract] [Full Text] [Related]
9. Acute cellular rejection during effective early prophylactic OKT3 monoclonal antibody treatment after renal transplantation.
Haak HH; Weening JJ; Rischen-Vos J; Daha MR; van Es LA; van der Woude FJ
Transplantation; 1989 Aug; 48(2):352-4. PubMed ID: 2526973
[No Abstract] [Full Text] [Related]
10. Fine-needle aspiration cytology during treatment with orthoclone monoclonal antibody OKT3 for acute cellular rejection after renal transplantation.
Hansen BL; Foged N; Nielsen E; Elbirk A; Rohr N; Svendsen V; Birkeland SA
Transplant Proc; 1988 Aug; 20(4):626-8. PubMed ID: 2970142
[No Abstract] [Full Text] [Related]
11. Prophylactic use of anti-CD3 monoclonal antibody WT32 in kidney transplantation.
Frenken LA; Hoitsma AJ; Tax WJ; Koene RA
Transplant Proc; 1991 Feb; 23(1 Pt 2):1072-3. PubMed ID: 1824887
[No Abstract] [Full Text] [Related]
12. The use of an anti-CD3 priming dose to enhance the immunosuppressive potency of monoclonal and polyclonal T-cell antisera.
Sherburne CG; Onyekaba CO; Condie RM
Transplant Proc; 1991 Feb; 23(1 Pt 1):626-9. PubMed ID: 1824996
[No Abstract] [Full Text] [Related]
13. Advantages of F(ab')2 fragments of anti-CD3 monoclonal antibody as compared to whole antibody as immunosuppressive agents in mice.
Hirsch R; Bluestone JA; Bare CV; Gress RE
Transplant Proc; 1991 Feb; 23(1 Pt 1):270-1. PubMed ID: 1824981
[No Abstract] [Full Text] [Related]
14. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
Norman DJ; Barry JM; Bennett WM; Munson JL; Meyer M; Henell K; Kimball J; Hubert B
Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
[No Abstract] [Full Text] [Related]
15. Suppression of the humoral response to anti-CD3 mAB by pretreatment with anti-CD4 mAB.
Hirsch R; Chatenoud L; Gress RE; Bach JF; Sachs DH; Bluestone JA
Transplant Proc; 1989 Feb; 21(1 Pt 1):1015-6. PubMed ID: 2523111
[No Abstract] [Full Text] [Related]
16. In situ antigenic modulation of human graft-infiltrating T cells is induced by OKT3 treatment.
Caillat-Zucman S; Legendre C; Noel LH; Bach JF; Kreis H; Chatenoud L
Transplant Proc; 1990 Aug; 22(4):1782. PubMed ID: 2143860
[No Abstract] [Full Text] [Related]
17. The successful use of repeated courses of OKT3 for hepatic allograft rejection using %T3 cells to adjust dose.
Colonna JO; Millis JM; Martello J; Levy P; Iwaki Y; Brems JJ; Klein AS; Hiatt JR; Busuttil RW
Transplant Proc; 1989 Feb; 21(1 Pt 2):2247-8. PubMed ID: 2523600
[No Abstract] [Full Text] [Related]
18. Anti-Leu2a (anti-CD8) monoclonal antibody therapy: antibody-mediated cell clearance in vivo requires Fc-FcRII interaction.
Wee SL; Phelan JM; Preffer FI; Colvin RB; Cosimi AB
Transplant Proc; 1989 Feb; 21(1 Pt 1):117-8. PubMed ID: 2495592
[No Abstract] [Full Text] [Related]
19. OKT3 vs ALG induction therapy in combined pancreas-kidney transplantation.
Knechtle SJ; Pirsch JD; Groshek M; Reed A; D'Alessandro AM; Kalayoglu M; Belzer FO; Sollinger HW
Transplant Proc; 1991 Feb; 23(1 Pt 2):1581-2. PubMed ID: 1846478
[No Abstract] [Full Text] [Related]
20. Degree of modulation of cell-surface CD3 by anti-lymphocyte therapies.
Henell KR; Bakke A; Kenny TA; Kimball JA; Barry JM; Norman DJ
Transplant Proc; 1991 Feb; 23(1 Pt 2):1070-1. PubMed ID: 1824886
[No Abstract] [Full Text] [Related]
[Next] [New Search]
